Risk of Chondrosarcoma Transformation from Multiple Hereditary Exostosis Under the Age of 18, and Suggestion for Screening Protocol. Literature Review.
Hajer Al Saidi1✉ORCID, Aisha Al Sariri1, Amal Al Omairi1, Quds Al Rashdi1, Zayana Al M'awali1, Humaid Al Farii2
- 1 Sultan Qaboose University
- 2 Sultan Qaboose University Hospital
Received 22 October 2026 · Accepted 26 October 2026 · Published 26 October 2026 · Corrected 9 November 2026
DOI: https://doi.org/10.5281/zenodo.23675457
Article PDF · Original poster (PDF)
- views
- 7
- downloads
- 9
- countries
- 6
Since publication · journal site and Zenodo archive · robots excluded
Abstract
Introduction
Multiple hereditary exostosis (MHE) is a rare autosomal dominant condition with a prevalence of 1 in 50,000. MHE usually occurs in long bones such as the femur, tibia, and humerus. Malignant transformation into chondrosarcoma is rare and occurs in about 3-5%, usually at the 4th and 7th decade of life.
Materials and methods
The research question and inclusion criteria were established in advance. Inclusion criteria were: all levels of evidence, MHE with documented malignant transformation, patients aged ≤18 years, both male and female patients, and studies involving human subjects. Online databases PubMed and Google Scholar were used to identify literature on malignant transformation in children with MHE. No restrictions were applied regarding publication language or date. An Excel spreadsheet was used to record the relevant data obtained from the included studies.
Results
A total of 5 patients were identified. Four patients were male (80%), and the mean age was 11.4 years. The mean duration of symptoms before consultation was 8 months. The most common presenting symptoms were pain and swelling; the common sites were the femur and fibula. Four patients had low-grade chondrosarcoma (80%). All patients underwent tumor resection. Three patients had follow-up data available, with a mean follow-up duration of 4.5 years, during which no recurrences were reported.
Conclusion
Given the extremely low prevalence of malignant transformation in MHE at pediatric age and the limited data primarily derived from case reports, this study does not support the necessity of routine screening for malignant transformation in patients with MHE. It is recommended to space the surveillance protocol by skeletal survey at intervals of 2-3 years for asymptomatic children. Further studies extracted from larger databases are warranted to support a strong recommendation.
Original poster
Related posters
OncologyMeasles in Pediatric OncologyF. Kouzi, K. Elmkaddem, S. Bouramdane and 1 other
OncologyUnusual EMA and pan-keratin negative epithelioid sarcomaA. Alpeza, K. Gregorović, D. Alpeza and 4 others
OncologyIn Silico Discovery and Bioactivity of Beta-Carboline Derivatives as Potential Payloads for Chitosan-Based Breast Cancer Delivery SystemsM. Izzuddin, N. Pungot, M. Jamil and 4 others
OncologyTargeted therapy in Oncology: breast cancerM. Chennaq, I. Naffi, S. El Medkouri and 1 other